Wellesley Pharmaceuticals Developer of Paxerol

100 million people in the US suffer from a problem for which we have a strong solution and six patents issued.


Wellesley Pharmaceuticals is in development of an innovative, patented drug for treating Nocturia (frequent urination at night). Currently there are no drugs on the market focused on nocturia and Wellesley plans to be first to market in the space. We believe that our proprietary drug, Paxerol™, positions us to be the industry leader, addressing a massive unmet clinical need.


Paxerol offers significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow us to provide relief to hundreds of millions of people.

© 2014 Wellesley Pharmaceuticals,   All Rights Reserved